Table.
Novel antiarrhythmic agents (ClinicalTrials.gov or EU Clinical Trials Register identifiers).
| Target | Agent | Status |
|---|---|---|
| NaV and KV | Vernakalant | Promising phase I-III data both in terms of conversion and maintenance of nSR (see review: Vasc Health Risk Manag. 2013; 9: 165–175.) Phase IV trial ongoing |
| IK,ACh | NTC-801 | Phase II terminated; failed to meet primary end point to reduce AF burden or secondary end point to reduce AF duration or the number of AF episode |
| IKur | MK-0448 | Failed to alter ARP in humans |
| BMS-919373 | Ongoing clinical studies assessing AF burden in pAF patients (NCT02156076) and effect in ERP (NCT02153437) in subjects with dual chamber pacemaker | |
| F373280 | Currently being evaluated for its ability to maintain nSR after electrical cardioversion in pAF patients with HF (NCT01831856) | |
| XEND0103/ S66913 | Currently being evaluated in phase II clinical studies to assess efficacy in reducing AF burden in pAF patients (2014-002333-63) and pAF patients with implanted pacemaker (2013-004456-38) | |
| IK,ACh or dual IK,ACh / IKur inhibitor | OPC- 108459 | Ongoing phase I studies to assess safety (NCT02069119) and efficacy to cardiovert AF in paroxysmal and persistent AF (NCT01483183) |
| RyR | S107 | No human data |
| RyR | JTV-519 (K201) | Phase II terminated (NCT00626652), data not available |
| Gap Junction | ZP123 | Phase II terminated (NCT00901563), no data available |
| Gap Junction | GAP-134 | Phase I completed (NCT00510029, NCT00543946, NCT00783341) |